DelveInsight’s, “HPK1 inhibitors Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in HPK1 inhibitors pipeline landscape. It covers the HPK1 Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HPK1 Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the HPK1 Inhibitors Pipeline. Dive into DelveInsight’s comprehensive report today! @ HPK1 Inhibitors Pipeline Outlook

Key Takeaways from the HPK1 Inhibitors Pipeline Report

• In May 2025, Treadwell Therapeutics Inc. announced a study will be a first-in-human study evaluating the safety and tolerability of CFI-402411 in subjects with advanced solid malignancies, when CFI-402411 is administered as a single agent or in combination with pembrolizumab. CFI-402411 is an oral pill that blocks the function of HPK1. Blocking HPK1 could stimulate an immune response against the tumor in patients. This immune response could be further enhanced when combined with pembrolizumab. The data obtained from this study will determine the dose and schedule and subject selection for further clinical studies.
• DelveInsight’s HPK1 Inhibitors Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for HPK1 Inhibitors treatment.
• The leading HPK1 Inhibitors Companies such as TradeWell Therapeutics, BeiGene, ABM Therapeutics, Nimbus Therapeutics, Arvinas and others.
• Promising HPK1 Inhibitors Pipeline Therapies such as CFI-402411, Pembrolizumab, PRJ1-3024 and others.

Stay ahead with the most recent pipeline outlook for HPK1 Inhibitors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ HPK1 Inhibitors Treatment Drugs

HPK1 Inhibitors Emerging Drugs Profile

• BGB-15025: BeiGene

BGB-15025 is an investigational hematopoietic progenitor kinase 1 (HPK1) inhibitor discovered and being developed by BeiGene. HPK1 is a key negative feedback regulator of T-cell receptor signaling, which is believed to play a key role in antitumor immune response. In preclinical studies, the inhibition of HPK1 enhanced T-cell activation, which is expected to enhance the anti-tumor activity of anti-PD-1 inhibitors such as BeiGene’s tislelizumab. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of solid tumour.

• CFI-402411: Tradewell Therapeutics

CFI-402411 is a highly potent inhibitor of HPK1, which in preclinical studies has been shown to have an immune-activating effects including the alleviation of inhibition of T cell receptors (TCR), disruption of abnormal cytokine expression, alteration of the tumor immunosuppressive environment through effector cells (i.e. Regulatory T cells or Treg), and potent anti-leukemic effects in several mouse models. TWT-101 is a Phase I/II clinical trial of CFI-402411 in advanced solid malignancies. The study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CFI-402411, as well as to determine optimal dosing as a monotherapy and in combination with the anti-PD1 antibody, pembrolizumab.

• NDI-101150: Nimbus Therapeutics

NDI-101150 is a potent, selective, oral inhibitor of hematopoietic progenitor kinase 1 (HPK1), with a different immunotherapy mechanism to other checkpoint inhibitors. NDI-101150 reactivates anti-tumor activity of T-cells, B-cells and dendritic cells (DCs), even under immunosuppressive conditions. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Solid Tumor.

The HPK1 Inhibitors Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of HPK1 Inhibitors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HPK1 Inhibitors Treatment.
• HPK1 Inhibitors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HPK1 Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HPK1 Inhibitors market

Explore groundbreaking therapies and clinical trials in the HPK1 Inhibitors Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New HPK1 Inhibitors Drugs

HPK1 Inhibitors Companies

TradeWell Therapeutics, BeiGene, ABM Therapeutics, Nimbus Therapeutics, Arvinas and others.

HPK1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

HPK1 Inhibitors Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Unveil the future of HPK1 Inhibitors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ HPK1 Inhibitors Market Drivers and Barriers

Scope of the HPK1 Inhibitors Pipeline Report

• Coverage- Global
• HPK1 Inhibitors Companies- TradeWell Therapeutics, BeiGene, ABM Therapeutics, Nimbus Therapeutics, Arvinas and others.
• HPK1 Inhibitors Pipeline Therapies- CFI-402411, Pembrolizumab, PRJ1-3024 and others.
• HPK1 Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HPK1 Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on HPK1 Inhibitors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ HPK1 Inhibitors Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. HPK1 inhibitors: Overview
4. Mechanism of action
5. Pipeline Therapeutics
6. Therapeutic Assessment
7. HPK1 inhibitors – DelveInsight’s Analytical Perspective
8. Late Stage Products (Phase III)
9. Drug name: Company name
10. Drug profiles in the detailed report…..
11. Mid Stage Products (Phase II)
12. Drug name: Company name
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I/II)
15. CFI-402411: Tradewell Therapeutics
16. Preclinical Stage Products
17. HPK1 (I-O Program): Arvinas
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HPK1 inhibitors – Collaborations Assessment- Licensing / Partnering / Funding
21. HPK1 inhibitors – Unmet Needs
22. HPK1 inhibitors – Market Drivers and Barriers
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hpk1-inhibitors-pipeline-insight